R9156

Raltitrexed

≥98% (HPLC), solid

• 别名: L-Glutamic acid, N-((5-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl), ICI-D-1694, ZD-1694
• 经验公式（希尔记法）: C₂₁H₂₂N₄O₆S
• CAS号: 112887-68-0
• 分子量: 458.49
• UNSPSC代码: 12352200
• PubChem化学物质编号: 329824044
• NACRES: NA.77

属性

• 方案: ≥98% (HPLC)
• 表单: solid
• 颜色: off-white to light yellow
• 溶解性: H₂O: ≥10 mg/mL; DMSO: ≥40 mg/mL
• 创始人: AstraZeneca
• 储存温度: 2-8°C
• SMILES字符串: O=C1NC(C)=NC2=C1C=C(CN(C3=CC=C(C(N[C@H](CCC(O)=O)C(O)=O)=O)S3)C)C=C2

说明

生化/生理作用

Raltitrexed is a folate-based inhibitor of thymidylate synthase (TS) that is rapidly and extensively metabolized to its more potent polyglutamate derivatives.

Raltitrexed is a folate-based inhibitor of thymidylate synthase (TS) that is rapidly and extensively metabolized to its more potent polyglutamate derivatives. By inhibiting the formation of precursor pyrimidine nucleotides, raltitrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cells.

特点和优势

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

安全信息

• 象形图: GHS06,GHS08
• 警示用语：: Danger
• 危险声明: H300,H360
• 预防措施声明: P201 - P301 + P310 + P330
• 危险分类: Acute Tox. 2 Oral - Repr. 1B
• 储存分类代码: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• WGK: WGK 2
• 闪点(°F): Not applicable
• 闪点(°C): Not applicable
• 个人防护装备: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges